D Sahin, N Soyer, M Yeral, S Namdaroglu, F Hindilerden, I Aydogdu, Hba Ozturk, B Turgut, O Bilgir, M S Dal, A Gunes, M H Dogu, S Demircioglu, A Tombak, F Vural, E Gulturk, S Korkmaz, T Ulas, B Eser, F Altuntas
{"title":"结外鼻型NK/ t细胞淋巴瘤治疗：来自一项多中心研究的分析","authors":"D Sahin, N Soyer, M Yeral, S Namdaroglu, F Hindilerden, I Aydogdu, Hba Ozturk, B Turgut, O Bilgir, M S Dal, A Gunes, M H Dogu, S Demircioglu, A Tombak, F Vural, E Gulturk, S Korkmaz, T Ulas, B Eser, F Altuntas","doi":"10.4103/njcp.njcp_499_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), or nasal NK/T-cell lymphoma is the most common cause of the syndrome known as \"fatal midline granuloma.\"</p><p><strong>Aim: </strong>In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.</p><p><strong>Methods: </strong>Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.</p><p><strong>Results: </strong>Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.</p><p><strong>Conclusion: </strong>The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.</p>","PeriodicalId":19431,"journal":{"name":"Nigerian Journal of Clinical Practice","volume":"28 5","pages":"602-607"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study.\",\"authors\":\"D Sahin, N Soyer, M Yeral, S Namdaroglu, F Hindilerden, I Aydogdu, Hba Ozturk, B Turgut, O Bilgir, M S Dal, A Gunes, M H Dogu, S Demircioglu, A Tombak, F Vural, E Gulturk, S Korkmaz, T Ulas, B Eser, F Altuntas\",\"doi\":\"10.4103/njcp.njcp_499_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), or nasal NK/T-cell lymphoma is the most common cause of the syndrome known as \\\"fatal midline granuloma.\\\"</p><p><strong>Aim: </strong>In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.</p><p><strong>Methods: </strong>Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.</p><p><strong>Results: </strong>Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.</p><p><strong>Conclusion: </strong>The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.</p>\",\"PeriodicalId\":19431,\"journal\":{\"name\":\"Nigerian Journal of Clinical Practice\",\"volume\":\"28 5\",\"pages\":\"602-607\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nigerian Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/njcp.njcp_499_24\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/njcp.njcp_499_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study.
Background: Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), or nasal NK/T-cell lymphoma is the most common cause of the syndrome known as "fatal midline granuloma."
Aim: In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.
Methods: Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.
Results: Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.
Conclusion: The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.
期刊介绍：
The Nigerian Journal of Clinical Practice is a Monthly peer-reviewed international journal published by the Medical and Dental Consultants’ Association of Nigeria. The journal’s full text is available online at www.njcponline.com. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal makes a token charge for submission, processing and publication of manuscripts including color reproduction of photographs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
